Compare iShares MSCI France ETF (EWQ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Pfizer Inc — how do they compare? iShares MSCI France ETF trades at $41.41 (market cap $330.91M), while Pfizer Inc trades at $28.13 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 479.2× iShares MSCI France ETF's market cap, and Pfizer Inc pays a 6.18% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Pfizer Inc for 158 Days on average.
| EWQ | PFE | |
|---|---|---|
Market Cap | $330.91M | $158.56B |
Volume | 556,654 | 44,138,282 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $29.02 |
52-Week Low | $41.32 | $23.67 |
Typical Hold Time | 55 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is currently trading at $41.34, down 1.12% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock faces significant technical pressure with moving averages signaling strong selling momentum. Recent news highlights European market volatility driven by ECB rate hikes and energy price inflation, creating headwinds for European-focused investments.
The outlook remains cautious as monetary tightening and geopolitical risks weigh on European equities. Key support sits at $41 with resistance at $42, while oversold conditions suggest potential for near-term stabilization. However, sustained recovery depends on easing inflation pressures and improved eurozone economic sentiment.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
